Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston
3
×
boston blog main
boston top stories
life sciences
national blog main
alnylam pharmaceuticals
aminolevulinic acid
clinical trials
drugs
givosiran
rna interference
accelerated approval
acute hepatic porphyria
acute hepatic porphyrias
akin akinc
biopharma
biotech
deals
duchenne
europe blog main
europe top stories
fda
licensing
m&a
muscular dystrophy
national top stories
onpattro
patisiran
paul matteis
roche
sarepta therapeutics
stifel financial
What
medicine
3
×
rna
second
3
×
alnylam
approval
drug
fda
interference
pharmaceuticals
rnai
seek
speedy
ago
betting
billion
biopharma
cleared
data
deal
duchenne
far
gene
historic
indicated
market
nasdaq
new
nod
ok
puts
quick
recently
roche
sarepta
swiss
therapeutics
therapy
weeks
won
won’t
Language
unset
Current search:
second
×
medicine
×
boston
×
@xconomy.com
4 years ago
Roche Puts Up Historic $1.15B for Sarepta Duchenne Gene Therapy Deal
@xconomy.com
5 years ago
Alnylam Won’t Seek Quick FDA Nod For Second RNAi Drug
@xconomy.com
5 years ago
With New Data, Alnylam Could Seek Speedy OK For Second RNAi Drug